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Human amyloid deposits always contain the normal plasma protein serum
amyloid P component (SAP), owing to its avid but reversible binding to all
amyloid fibrils, including the amyloidb (Ab) fibrils in the cerebral parenchyma
plaques and cerebrovascular amyloiddeposits ofAlzheimer’s disease (AD) and
cerebral amyloid angiopathy (CAA). SAP promotes amyloid fibril formation
in vitro, contributes to persistence of amyloid in vivo and is also itself directly
toxic to cerebral neurons. We therefore developed (R)-1-[6-[(R)-2-carboxy-
pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid (CPHPC), a
drug that removes SAP from the blood, and thereby also from the cerebrospinal
fluid (CSF), in patientswithAD.Herewe report that, after introduction of trans-
genic human SAP expression in the TASTPM double transgenic mouse model
of AD, all the amyloid deposits contained human SAP. Depletion of circulating
human SAP by CPHPC administration in these mice removed all detectable
human SAP from both the intracerebral and cerebrovascular amyloid. The
demonstration that removal of SAP from the blood and CSF also removes it
from these amyloid deposits crucially validates the strategy of the forthcoming
‘Depletion of serum amyloid P component in Alzheimer’s disease (DESPIAD)’
clinical trial of CPHPC. The results also strongly support clinical testing of
CPHPC in patients with CAA.
1. Background
The amyloid fibrils which are deposited as the pathognomonic intracerebral
amyloid plaques and cerebrovascular amyloid deposits in Alzheimer’s disease
(AD) are composed of the Ab peptide [1]. Ab is derived by sequential proteo-
lytic cleavage of the amyloid precursor protein (APP) first by b-secretase [2],
and subsequently by the g-secretase complex, of which the presenilin proteins
(PSEN 1, PSEN 2) are the catalytic subunits [3]. Autosomal dominant hereditary
AD is caused by mutations in, or duplication of, the APP gene and by
mutations in the PSEN 1, PSEN 2 genes [4]. The APP–Ab pathway thus
must have a causal role in neurodegeneration but neither the actual pathogenic
moiety nor the mechanisms underlying neuronal damage in AD are known and
all attempts so far at therapeutic targeting of this pathway have failed through
lack of efficacy and/or drug toxicity [5]. In contrast, the Ab amyloid in sporadic
cerebral amyloid angiopathy (CAA) clearly causes the structural disruption
which results in vascular dysfunction and cerebral haemorrhage, just as the
amyloid deposits in the tissues cause disease in systemic amyloidosis [6].
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of local amyloidosis.
Serumamyloid P component (SAP) has longbeen identified
by our laboratory as a therapeutic target in all forms of amyloid
deposition [7–9]. SAP is an invariant, normal, highly proteinase
resistant, plasma glycoprotein which is always present in all
human amyloid deposits [10], including the Ab amyloid of
AD and CAA [11–13]. SAP binds avidly but reversibly to all
amyloid fibrils, including thosewhichare the direct causeofdis-
ease in systemic amyloidosis [6] and in CAA [14], and those in
ADwhere their role in pathogenesis, if any, is not known. Bind-
ing of SAP promotes amyloid fibrillogenesis in vitro [15,16] and
stabilizes the fibrils, protecting them from proteolytic cleavage
and acting as an anti-opsonin to prevent their destruction by
phagocytic cells [8,17]. SAP thus is likely to contribute signifi-
cantly to the unique persistence of amyloid deposits in vivo
[18] that contrasts with the generally very efficient clearance of
autologous debris from the extracellular space.
In addition, unrelated to its role in amyloid deposits,
human SAP is directly neurotoxic to cerebral neurons
[19–21]. It binds to them, is internalized, traffics to the nucleus
[22]where it binds to chromatin [23], and leads to apoptotic cell
death. SAP is synthesized and catabolized only by the liver [24]
and human SAP is not expressed in the brain [25], which it
enters only from the blood. It is normally present in the cere-
brospinal fluid (CSF) at only about one-thousandth of the
plasma concentration [26,27]. The binding of SAP to intracereb-
ral Ab amyloid deposits and plaques must increase the brain
content of SAP [28]. The reversible non-covalent interaction
with amyloid fibrils [10] must then also provide an increased
local concentration of free SAP adjacent to amyloid deposits.
Furthermore, other known risk factors for dementia, including
advanced age, cerebral haemorrhage, traumatic brain injury
(TBI) and severe or repeated non-penetrating head injury, all,
certainly or probably, increase exposure of the brain to SAP,
which could then contribute to neurodegeneration. In old
age, the increase is simply the prolonged duration of exposure
to normal CSF SAP concentrations but the other conditions,
with compromised cerebral vascular integrity, enable plasma,
with its 1000-fold higher SAP concentration, to enter the
cerebral substance.
Our drug, (R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-
hexanoyl]pyrrolidine-2-carboxylic acid (CPHPC), was devel-
oped to abrogate the pathogenic contribution of human SAP to
amyloid formation and persistence [9]. CPHPC is specifically
boundbyhumanSAP in the circulation to form stable complexes
of pairs of native pentameric SAP molecules cross-linked by the
drug [9]. These complexes are immediately cleared by the liver,
leading safely and effectively to almost complete depletion of
plasma SAP for as long as the drug is administered [9,29]. We
have shown that depletion of plasma SAP by administration of
CPHPC to patients with AD leads to complete disappearance
of SAP from the CSF [30]. CPHPC also enters the CSF in AD
patients [30] and is thus available to inhibit binding of SAP to
amyloid fibrils. Hence the rationale for University College Lon-
don’s forthcoming ‘Depletion of serum amyloid P component
in Alzheimer’s disease (DESPIAD)’ clinical trial of CPHPC in
AD is: (i) that removal of all SAP from the brain by CPHPC
will abrogate the direct neurotoxicity of human SAP; and (ii)
that stripping of SAP from the cerebral plaques and cerebrovas-
cular Ab amyloid deposits will promote amyloid clearance.
The same rationale underpins further planned clinical studies
of CPHPC in CAA and TBI.We already know that the first goal of removing all SAP
from the CSF will be achieved [30], but it is obviously not
possible to directly demonstrate removal of SAP from amy-
loid deposits in living human subjects. Indeed, although
CPHPC treatment very substantially reduces the amount of
SAP in systemic amyloid deposits, the affinity of binding of
SAP to CPHPC is not sufficient for the drug to strip all
SAP from its avid multivalent binding to the very abundant
amyloid deposits that are present in these patients [29]. In
contrast, cerebral and cerebrovascular amyloid deposits are
several orders of magnitude less abundant than the deposits
in systemic amyloidosis. Also the intracerebral plaques are
exposed to a 1000-fold lower SAP concentration than is pre-
sent in the plasma. On purely thermodynamic grounds,
therefore, CPHPC should completely remove SAP from cerebral
Ab amyloid plaques and CAA deposits in patients.
Mouse SAP binds about 30-fold more weakly than human
SAP to all known ligands so that, although mouse SAP is pre-
sent in murine systemic amyloid deposits, it is not found in
cerebral Ab amyloid in mouse models of human AD [31],
and circulating mouse SAP is not depleted by CPHPC
in vivo [9]. In order to investigate the capacity of CPHPC to
remove bound SAP from amyloid deposits in the brain, we
therefore introduced transgenic expression of human SAP
into the TASTPM double transgenic mouse model of familial
AD [32]. The TAS and TPM transgenes encode pathogenic
variants of human APP and human presenilin-1, respectively,
and the mice develop abundant intracerebral and cerebrovas-
cular human Ab amyloid deposits. Here we report that the
triple transgenic mice showed the expected presence of
human SAP in all their amyloid deposits and that it was com-
pletely removed by sustained depletion of circulating human
SAP produced by long-term administration of CPHPC.2. Material and methods
2.1. Human CAA tissue
Formalin fixed wax embedded blocks of cerebral cortex tissues
from nine patients with histologically confirmed sporadic
CAA were provided by the Queen Square Brain Bank for
Neurological Disorders, UCL.
2.2. Transgenic mice
TASTPM transgenic mice [32], homozygous for both the
TAS and TPM transgenes, were provided by GlaxoSmithKline.
The human SAP gene was amplified by PCR using Phusion
High-Fidelity DNAPolymerase (NEB) and cloned in a plasmid
vector as a 2.6 kb HindIII fragment, comprising the 1 kb
SAP gene with 0.6 and 1 kb of 50 and 30 flanking sequence,
respectively. After verifying the exon sequences, the 2.6 kb
HindIII insert was released from the vector, gel purified and
microinjected into pronuclei of C57BL/6J mouse embryos to
generate transgenic mice expressing human SAP on the
inbred C57BL/6J background. Lines were established and
maintained hemizygous by backcrossing to wild-type
C57BL/6J partners. TASTPM, human SAP triple transgenic
mice were generated by crossing TASTPM homozygous mice
with human SAP transgenic mice. The progeny were thus
either hemizygous for all three transgenes or were hemizygous
for the TAS and TPM transgenes. Genotypes were assessed by
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males and females.
2.3. Immunoassay for SAP
SAP protein concentrations were assayed by electroimmuno-
assay or immunoradiometric assay, as described previously
[27,33].
2.4. Immunohistochemical staining for Ab and SAP
Immunoperoxidase histochemistry was performed on a
Ventana Discovery XT staining platform using the Ventana
DAB Map Kit. Wax sections of formalin fixed tissue were pre-
treated with formic acid (for Ab staining) or with Ventana
Protease 3 (for SAP staining) and blocked for 8 min using
Superblock (Medite). A mouse monoclonal primary antibody
was used for detection of Ab (Dako, clone 6F-3D), and an in-
house monospecific polyclonal rabbit antiserum was used to
detect human SAP, and counterstained with haematoxylin.
Immunofluorescence histochemistry was performed on
14 mm frozen sections of unfixed frozenmouse brains. Sections
were dried at room temperature and stored at 2208C before
use. Non-specific binding was blocked with 2% w/v BSA,
0.1% Triton X-100 in PBS, and SAP was then detected with
the monospecific rabbit anti-human SAP antibody followed
by Alexa-488 labelled anti-rabbit IgG antibody, followed by
counterstaining with bisbenzimide.
2.5. Histochemical staining for amyloid
Amyloid deposits in histological sections were stained with
Congo red [34] and identified by their pathognomonic
green birefringence in high intensity cross polarized light.3. Results
3.1. SAP in human cerebral and cerebrovascular Ab
amyloid deposits
The universal presence of human SAP in Ab amyloid has been
extensively confirmed since our original 1984 observations on
sporadic and hereditary CAA [11]. However, in order to vali-
date our methods for subsequent application to studies in
human SAP transgenic mice, we examined brain sections
from nine confirmed sporadic CAA patients using Congo red
staining for amyloid and immunohistochemical staining of
adjacent sections for SAP and Ab. In each human case, SAP
and Ab staining were observed in congruent patterns in
blood vessel walls (figure 1), and in eight of the nine cases,
the SAP stainingwas strong. In seven of the cases, intracerebral
Ab amyloid plaques were also present. They stained with
anti-SAP antibodies but much less intensely than the vascular
amyloid in the same sections (figure 1e,f). Diffuse immunostain-
ing for SAP was also seen in perivascular areas (figure 1g– j),
presumably reflecting recent vascular leakage.
3.2. Ab amyloid deposition in TASTPM mice
Almost all patients with AD have CAA, although usually of
lesser severity than in patients with typical sporadic CAA
and predominantly affecting capillaries rather than arterioles.Similar cerebrovascular amyloid deposition is seen in mouse
models of AD [31,35]. The double transgenic TASTPM mice
have been reported to develop immunologically detectable
human Ab deposits from three months of age and amyloid
plaques by six months [32]. Here we also observed extensive
vascular amyloid deposition at six months of age in TASTPM
mouse brains, with pathognomonic green birefringence in
polarized light of both plaques and cerebral blood vessels
stained with Congo red (figure 2).
3.3. Human SAP transgenic mice and CPHPC
administration
Several human SAP transgenic lines were established, two of
which were expanded for further study. The serum concen-
tration of human SAP in line 9 transgenic mice was mean
(s.d.) 29.2 (4.0) mg l21 (n ¼ 6), closely corresponding to the
human reference range [27]. In contrast, the human SAP con-
centration in sera of line 38 transgenic mice was mean (s.d.)
216.9 (154.9) mg l21 (n ¼ 31) (figure 3a), with no statistically
significant difference between males and females. Following
administration to line 38 mice of CPHPC at 5 mg ml21 in
their drinking water, the serum concentration of human
SAP rapidly fell to 1.33 (0.64) mg l21 (n ¼ 32) (figure 3a)
and remained reduced by more than 97% for as long as
drug exposure continued.
3.4. Human SAP transgenic TASTPM mice
After introduction of the human SAP transgene into TASTPM
mice by crossing them with line 38, the circulating concen-
tration of human SAP was in the same range as in the
transgenic mice on the wild-type background (figure 3b).
When examined at 20 months of age, both the vascular and
plaque Ab amyloid deposits were positive for human SAP
by immunoperoxidase staining of sections of formalin fixed
wax embedded brain (figure 4a–c), while control sections
from age matched TASTPM mice without the human SAP
transgene were entirely negative (figure 4f–h). This was con-
firmed by immunofluorescence staining of frozen sections of
unfixed tissue from human SAP transgenic TASTPM mice
(figure 4d,e) and control TASTPM animals (figure 4i,j ).
3.5. Effects of CPHPC administration and SAP depletion
Administration to human SAP transgenic TASTPM mice of
5 mg ml21 of CPHPC in drinking water, from age four or six
months until age 20months, had no discernible adverse effects.
The body weights of CPHPC-treated mice were indistinguish-
able from those of controls (data not shown). The circulating
human SAP concentration in CPHPC-treated animals fell to
between 0.1 and 2.9 mg l21 in samples taken during treatment
and at termination (figure 3b). Furthermore, no immunoperox-
idase staining for human SAP was observed in the amyloid
deposits after CPHPC treatment (figure 4k–m), in marked
contrast to the positive staining in untreated human SAP trans-
genic TASTPM mice (figure 4a–c). The immunoreactivity of
human SAP is diminished by standard formalin fixation and
wax embedding [36], and antigen retrieval techniques are
required for its optimal detection by immunoperoxidase stain-
ing. The presence of human SAP was therefore also sought by
immunofluorescence staining of cryosections of unfixed tissue.
(a)
(h) (i) ( j)
(b)
(c) (d)
(e) ( f )
(g)
Figure 1. Localization of SAP in human CAA. (a,b) Congo red stained section viewed with bright field illumination (a) and with intense crossed polarized light (b),
showing abundant amyloid in blood vessel walls. The arrowhead in (b) shows the white birefringence of collagen often seen in normal blood vessels, in contrast to
the green birefringence of Congo red stained amyloid. (c,d ) Immunoperoxidase staining for Ab (c) and SAP (d ), showing strong immunoreactivity in vessel walls. In
one vessel, the amyloid is mostly confined to one segment of the vessel wall (arrow in a–d ). (e,f ) Lower magnification images of the sections shown in (c,d ),
showing amyloid plaques which stain strongly for Ab and very weakly for SAP. Higher magnification images of the arrowed plaque are inset. (g– j ) Sections of an
amyloid-containing blood vessel surrounded by blood. (g,h) Congo red stained section viewed with bright field illumination (g) and with intense cross polarized
light (h). (i,j ) Immunostaining for Ab and SAP, respectively. The arrow in ( j ) shows diffuse staining in adjacent neural tissue, not associated with amyloid, likely
due to a microbleed. Scale bars, (a–d), 250 mm; (e,f ), 500 mm; (g– j), 250 mm.
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human SAP (figure 4n,o) with appearances indistinguishable
from those of tissues from control TASTPM mice without the
human SAP transgene (figure 4i,j ).3.6. Human SAP content of intracerebral plaques and
cerebrovascular amyloid deposits
In brain sections from human SAP transgenic TASTPM mice,
anti-SAP antibodies consistently stained the cerebrovascularamyloid deposits much more intensely than the parenchymal
amyloid plaques (figure 5), in both immunoperoxidase stain-
ing of formalin fixed wax embedded tissue (figure 5a,b) and
immunofluorescence staining of cryosections of unfixed
tissue (figure 5e,f ). The SAP content of cerebrovascular amy-
loid is thus considerably greater than that of plaque amyloid,
consistent with in vivo exposure of the plaques only to the
SAP concentration of CSF fluidwhich, in humans and presum-
ably also in mice, is about 1000-fold lower than the plasma
and extracerebral interstitial fluid concentration. Using up to
10-fold longer exposures, even trace immunofluorescent
(a) (b)
Figure 2. Cerebrovascular amyloid in TASTPM mice. Unfixed frozen brain sec-
tions from six-month-old female TASTPM mouse stained with Congo red
showing cerebrovascular amyloid (arrow) and cerebral plaque (arrowhead).
(a) Bright field illumination; (b) intense cross polarized light showing pathog-
nomonic green birefringence of Congo red bound to amyloid. Scale bar,
150 mm.
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Figure 3. Human SAP expression in transgenic mice, and depletion by
CPHPC. Human SAP concentrations in sera of individual transgenic mice,
while on water alone or water containing 5 mg ml21 CPHPC. (a) Line 38
human SAP transgenic C57BL/6 mice; (b) line 38 human SAP transgenic
TASTPM mice. Results are from males and females with no apparent
differences between sexes.
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(figure 5e,f ) and the abundance of SAP in the deposits
semi-quantitatively assessed. This confirmed that after CPHPC
treatment both the cerebrovascular deposits and the cerebral
plaques had been stripped of SAP (figure 5g,h), with staining
intensity not different from the background autofluorescence
of plaques in TASTPM controls with no human SAP transgene
(figure 5c,d ).4. Discussion
We have previously identified human SAP as a therapeutic
target in both systemic amyloidosis and in neurodegenera-
tive conditions associated with cerebral and cerebrovascular
Ab amyloid deposition [7–9]. We have also shown that
administration of the SAP depleting drug, CPHPC, produces
sustained depletion of plasma SAP for as long as the drug is
administered [29] and that depletion of circulating SAP leads
to complete disappearance of SAP from the CSF in patients
with AD [30]. Since SAP is not expressed in the human
brain [25], the SAP depletion effected by CPHPC should
abrogate the direct neurotoxicity of this plasma protein. How-
ever, for depletion of free soluble SAP to promote the desired
enhanced clearance of amyloid deposits, it should ideally
lead to essentially complete removal of SAP from its binding
to amyloid fibrils. This does not happen in systemic amyloi-
dosis because, despite the ability to safely administer high
doses of this non-toxic, non-metabolized drug, the CPHPC
concentrations which are attainable in vivo are not sufficient
to reverse the avid multivalent binding of the pentameric
SAP molecule to the very abundant amyloid fibrils. Even
after months of daily dosing with CPHPC, some SAP,
albeit a much reduced amount, remains associated with
visceral amyloid deposits [29]. Although no regression of
amyloid then ensues, observations in CPHPC-treated sys-
temic amyloidosis patients suggest that the treatment
nonetheless may reduce new amyloid accumulation and
stabilize the function of amyloidotic organs [29].
The situation regarding cerebral and cerebrovascular Ab
amyloid is radically different. The total mass of Ab amyloid
is extremely small in comparison with systemic amyloiddeposits. We therefore expected that plasma SAP depletion by
CPHPC would successfully remove all SAP bound to cerebral
parenchymal and vascular Ab amyloid deposits, and this has
been confirmed by the present observations. Furthermore, par-
enchymal plaques are exposed to about 1000-fold lower
ambient SAP concentrations in the CSF [26,30] than the cerebro-
vascular deposits bathed in plasma-derived extracellular fluid.
The relative quantities of bound SAP differ accordingly, as we
have confirmed here immunohistochemically, and this explains
why, over 30 years ago, we [11] and others [37] did not initially
detect SAP on the cerebral parenchymal plaques using much
less sensitive immunostaining procedures.
It is important to note that the present experiments were
not designed to show an effect of CPHPC treatment and
human SAP depletion on Ab amyloid load. TASTPM mice
strongly overexpress two different familial AD genes under
the mouse Thy-1 gene promoter [32] and develop extensive
cerebral amyloid plaques and CAA in the absence of
human SAP expression. It is therefore unlikely that their Ab
amyloid deposition will be detectably modulated by the
presence or depletion of human SAP.
The pathogenic role, if any, of the cerebral parenchymal Ab
amyloid plaques in AD and that appear soon after TBI [38] is
unknown, but an intervention which leads to clearance and/
or prevention of the deposits would be very informative.
This is one of the aims of our existing DESPIAD clinical trial
of CPHPC in patients with AD, scheduled to start in 2016. In
contrast to AD, theAb amyloid deposits in thewalls of cerebral
blood vessels in CAA are unequivocally the cause of vascular
dysfunction and cerebral haemorrhage in this very important
and prevalent disease [14]. Progressive deposition of amyloid
disrupts blood vessel structure with loss of smooth muscle
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Figure 4. Depletion of human SAP from cerebrovascular amyloid by CPHPC treatment of transgenic mice. Sections of formalin fixed wax embedded cerebral cortex
from 20-month-old mice stained with Congo red and viewed in bright field (a,f,k) or intense cross polarized illumination (b,g,l ), and also immunoperoxidase (IP)
stained with anti-human SAP antibodies (c,h,m). Unfixed frozen sections from the same tissues stained by immunofluorescence (IF) with anti-human SAP antibodies
(green) and bisbenzimide counterstain (blue) (d,i,n) and also viewed in phase contrast (e,j,o). (a– e) Human SAP transgenic TASTPM mouse, ( f– j ) TASTPM control
mouse, (k–o) CPHPC-treated human SAP transgenic TASTPM mouse. Amyloid-containing blood vessels are labelled with arrows, and example amyloid plaques are
indicated by arrowheads. Tissues in (a– c), ( f–h), (k–m) are from males and (d,e,i,j,n,o) from female mice.
(a)
(h)
(b)
(c) (d) (e) ( f ) (g)
Figure 5. Depletion of human SAP from cerebral plaques by CPHPC treatment of transgenic mice. (a,b) Sections of formalin fixed wax embedded cerebral cortex
from 20-month-old human SAP transgenic male TASTPM mice, immunoperoxidase stained with anti-human SAP antibodies, showing intense staining of vascular
amyloid (arrows) and very weak staining of intracerebral plaques (arrowheads). (c–h) Amyloid plaques (outlined) in unfixed frozen sections of cerebral cortex from
20-month-old female mice stained with fluorescent labelled anti-human SAP antibodies (green). (c,d ) TASTPM control; (e,f ) human SAP transgenic TASTPM; (g,h)
CPHPC-treated human SAP transgenic TASTPM. The green channel exposures used for panels (c–h) were 10 times longer than for figure 4d,i,n. At the exposure that
demonstrated SAP in the cerebrovascular amyloid in figure 4, there was no signal from the intracerebral plaques. Scale bars, (a,b), 100 mm; (c–h), 150 mm.
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delamination of the outer part of the tunicamedia. CAA is pre-
sent at autopsy in 20–40% of non-demented and 50–60%
of demented elderly populations, and in at least 90% of indi-
viduals with Alzheimer’s disease (AD) [14]. CAA causes
microbleeds and lobar intracerebral haemorrhages, comprising
up to 20% of haemorrhagic strokes [14]. CAA is also associated
with ischaemic brain injury, including small areas of infarction
[39] andwhitematter abnormalities [40], and it impairs normalvascular function [41,42]. The very high, approximately 10%,
annual rate of recurrent intracerebral haemorrhage in CAA
increases the long-term risk of dementia [43]. The spectrum
of vascular brain injury and dysfunction in CAA is also likely
to cause cognitive impairment, independently of cerebral
haemorrhage [44,45]. CAA is thus a particularly attractive indi-
cation both for an intervention designed to promote clearance
of amyloid and for abrogation of the direct neurotoxicity of
blood-derived SAP entering the brain.
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